other surfaces (plastic, collagen, and hydroxyapatite crystals). The effect ofGC on cell-bone attachment is blocked by the glycosylation inhibitor, tunicamycin, and the glycosylation modifier, swainsonine; this demonstrates that asparagine-linked oligosaccharides are involved in the stimulatory process. Flow cytometric analysis of GCtreated cells using a panel of fluoresceinated lectins confirms this by indicating a selective, enhanced exposure of plasma membrane-associated N-acetylglucosamine and N-acetylgalactosamine residues, sugars we have previously shown to be pivotal in MO-bone binding. Finally, progesterone, a known GC antagonist, blocks GC-stimulated resorption, macrophage-bone binding, and membrane oligosaccharide modification, presumably by competing Dr. Bar-Shavit is the recipient of an Arthritis Investigator Award from the Arthritis Foundation.
Introduction
One of the most common forms of treatment of inflammatory and immune-related disorders is the administration of glucocorticoids (GC).' These steroidal compounds are clearly effective in the short term, but their chronic administration results in a number of unwanted side effects, of which the most important are loss of bone (osteopenia) and spontaneous fracture. Because of the clinical importance of GC, these observations have prompted many studies that aimed to elucidate the mechanism of action of these compounds at the cellular level in bone.
The maintenance of skeletal mass is the result of a balance between bone formation and resorption. Consequently, steroidinduced osteopenia may result from decreased bone formation, increased resorption, or a combination of both. Studies of the effects of GC on the skeleton uniformly indicate that these compounds inhibit osteoblastic function (1-4) (i.e., bone formation) but are less clear about how they affect osteoclasts (i.e., bone resorption). For example, GCs usually block parathyroid hormone-stimulated resorption in fetal bone rudiments in organ culture (5) , but histological examination of these tissues taken from GC-treated patients and animals indicates an increase in the number of osteoclasts and no apparent decrease in resorptive activity (1, 2, (5) (6) (7) (8) (9) .
Previous attempts to explain the foregoing observation have focused largely on the observation that GC-treated patients or animals may develop secondary hyperparathyroidism, presumably through suppressed intestinal absorption of calcium (1, 2) . The logical consequence of this model is that the osteoclastic proliferation which accompanies GC treatment is mediated through parathyroid hormone secretion and that GC per se, do not directly stimulate bone resorption. This hypothesis, however, remains unproven and is particularly weakened by the observation that most GC-treated patients do not develop secondary hyperparathyroidism (2) .
Another explanation that might account for the apparent stimulation by GCs of resorption in vivo is the simplest one, namely, that these steroids enhance skeletal degradation by directly promoting the activity of resorptive cells. This hypothesis follows largely from the very recent observation that bone resorption by isolated osteoclasts in vitro is significantly enhanced by GC (M. Fallon, personal communication) and from our previous studies showing that a similar effect can be documented for other differentiated cells that belong to the mononuclear phagocyte family, i.e., macrophages (MO) (10) and MO polykaryons (multinucleated giant cells) (1 1).
In this study, we examine the mechanisms ofGC-stimulated resorption, particularly as it relates to the ability of resorptive cells to attach to bone, a step essential to efficient matrix degradation. The data show that GC markedly and specifically increase cell-bone binding and indicate that this stimulation is likely the result of alterations of cell surface glycoproteins.
Methods
The materials used in this study were obtained from the 
Binding assays
Particle binding. This method is described in detail in a previous publication (12) . Briefly, rat thioglycollate-elicited peritoneal cells are suspended in a-MOPS [a-MEM buffered to pH 7.4 with 3(N-morpholino)
propanesulfonic acid] at a concentration of 5 X 105/ml and 0.2-ml aliquots are pipetted into 6-mm-diam multiwell plates. After 45Ca-labeled bone particles 23-43 ,um in diameter are added to the MO-containing wells in 0.2-ml aliquots (1 mg/ml in a-MOPS). The plates are then incubated at 370C in air for an additional hour, and the nonadherent particles are removed by immersion and agitation in three successive changes of phosphate-buffered saline (PBS). 5% TCA is then added to each well to solubilize the residual attached particles, and the resultant radioactive slurry is dissolved in scintillation fluid (Scintiverse, Fisher Scientific Co., Allied Corp., Pittsburgh, PA) for counting. The net, cell-associated binding of particles is determined by subtracting the counts obtained from particles added to cell-free wells from counts derived from cultures that contain MO monolayers.
Calvarial binding (12) . Elicited peritoneal exudate cells in a-MOPS are plated into 60-mm tissue culture dishes and rinsed after 1 h of incubation to remove the nonadherent fraction. Bicarbonate buffered a-MEM supplemented with 2.5% fetal calf serum is then added to the dishes with GC or ethanol and, after an additional 24-72 h of culture, the plates are rinsed again to remove the remaining nonadherent cells.
The medium is then replaced with Ca++/Mg++-free PBS at 4VC. 20 min later, the attached MO are brought into suspension by gentle scraping with a rubber policeman. The MO are then labeled for i h at 370C with Na51CrO4 (sp act 250-500 ACi/mg Cr) (Amersham Corp., Arlington Heights, IL) (1 ACi/ 106 cells in a-MOPS), washed three times with cold a-MOPS, and suspended in the same medium at 1 X 106 cells/ml. 0.1-ml aliquots of the cell suspension are then pipetted onto the endocranial surface of freshly dissected rat calvaria that are obtained from 7-d-old rat pups and freed of their inner periosteum by mechanical stripping. The calvaria are placed, concave-side up, in multiwell culture dishes and the cells are added. After 1 h of incubation, the nonadherent cells are removed by sequentially rinsing the calvaria in PBS, and the adherent fraction is determined by y-scintography.
Hydroxyapatite binding. The protocol used is identical to the boneparticle binding assay. The particles are labeled by incubation with 45Ca (100 uCi/I0 mg per ml PBS) for 24 h.
Bone resorption
The extent of bone resorption is established from the cell-mediated 45Ca release from devitalized labeled bone particles as previously described (13) .
Cell number
The number of adherent cells is determined by the methylene blue binding technique (14) . In brief, cells are fixed overnight in 2.5% formaldehyde, washed in 0.1 M borate buffer (pH 8.5), and incubated for 10 min in methylene blue (1 mg/ml in borate buffer). The cells are then washed extensively in buffer to remove excess dye and extracted with 0.1 N HCi at 370C for 40 min to elute the cell-associated methylene blue. The eluate is measured spectrophotometrically at 650 nm. Dye binding is proportional to cell number (14) . This method is used to assure that the increase in bone-particle binding is not a result ofincreased MO attachment to the wells.
Flow cytometric analysis ofFITC-lectins binding Cells are prepared as for the calvarial binding assay but are not radiolabeled. After the cells are brought into suspension they are washed three times in PBS and resuspended to 2 X 106/0.5 ml in PBS. FITC lectins are then added to the suspension in the presence or absence of the competing sugars for 60 min at 40C. After three washes in PBS, the cells are suspended in PBS (2 X 106/2 ml) kept on ice, and analyzed immediately in a fluorescence-activated cell sorter (Epics V, Coulter Electronics Inc., Hialeah, FL).
Results
Incubation of MO with cortisol or dexamethasone significantly enhances cell-bone binding by 24 h and produces optimal stimulation by 48 h. At the later time, attachment is increased -175% relative to untreated cells and is evident whether binding is measured by the particle (Fig. 1) or calvarial (Fig. 2) assay. The stimulation of MO-bone binding by GC is dose dependent and is elicited at both physiological and pharmacological concentrations (Fig. 3) . In contrast, progesterone (Figs. 1-3 ) and 11-deoxycortisol (not shown) do not alter MO-bone binding.
Because MOs bind to a remarkably broad spectrum of substrates, it was of interest to determine the specificity of the GCstimulated attachment process. To this end, MO were preincubated with cortisol (1o-6 M) or dexamethasone (10-8 M) and later assayed for their ability to bind 45Ca-labeled hydroxyapatite particles, or, after radiolabeling with 5"Cr, to tissue culture plastic.
Fig. 4 shows that treatment with GC either had no effect or reduced the ability of MO to bind to hydroxyapatite or plastic. Similar results were obtained when a reconstituted Type I, collagen-coated surface was used as an attachment substrate for GC-treated MO (data not shown).
Membrane oligosaccharides are known to play a role in the recognition and attachment of cells to specific substrates, and we have previously shown (12) MO monolayers were pretreated with dexamethasone (10-8 M), cortisol (10-6 M), or progesterone (10-6 M) for the times indicated. The steroids were then removed, 45Ca-labeled bone particles were added, and the fraction of the particles bound after 1 h more of incubation was determined. Note that dexamethasone and cortisol, but not progesterone, significantly stimulate binding activity. Each point represents the mean of six replicate cultures ±SEM. The cells were then labeled with 5"Cr and added by aliquots onto the stripped endocranial surface of freshly dissected calvaria. After 1 h of incubation, the fraction of adherent cells was determined indirectly from the radioactivity associated with sequentially rinsed calvaria. Each point represents the mean counts from three calvaria. (Control, solid bars; cortisol, hatched bars; dexamethasone, stippled bars; progesterone, cross-hatched bars.) sonine (SW) (an agent known to alter glycosylation). Fig. 5 shows that each of these agents reduced basal (no cortisol) MObone attachment and blocked the stimulatory effect of cortisol on this process. Such inhibition of bone attachment was unassociated with change in cell number (data not shown).
These observations led us to test directly the effect of GC on the accessibility of cell surface oligosaccharides. Here, quantitative flow cytometry was used to analyze the binding ofspecific FITC-conjugated lectins by GC-treated and control MO. Fig.  6 demonstrates that GC treatment enhances the binding ofWGA and DBA, lectins that are specific for N-acetylglucosamine and N-acetylgalactosamine, which are sugars we have previously shown (12) MO monolayers were preincubated for 72 h with the indicated concentrations of dexamethasone, cortisol, or progesterone, and then assayed for binding activity. The data show that the GCs markedly increase particle attachment, whereas progesterone is ineffective. Each point represents the mean±SEM for six replicate cultures. of MO. We obtained similar results with the lectins GSA-2 and SBA (data not shown). On the other hand, no changes are evident in the binding of lectins specific for sugars that do not affect the cell bone attachment; for example, concanavalin, A specific for mannose residues, and Ricinus Communis agglutinin and peanut agglutinin, specific for galactose.
The final group of experiments tried to establish whether the action ofGC on MO is mediated through cytosolic receptors. We took advantage of the established ability of progesterone to compete for the GC receptor and found that, whereas progesterone alone does not affect MO-bone attachment, it inhibits the GC stimulation of the binding process (Fig. 7) . In a similar way, progesterone restricts the ability of dexamethasone to en- (Fig. 8) . Finally, the presence of progesterone blocks the development of lectin binding sites (exposed sugar residues) in GC-treated MO (Fig. 9 ).
Discussion
Bone resorption is a multistage process that involves, among other things, the attachment of cells to bone (13) . In the Introduction, we postulated that the resorption-stimulating activity of GC might be due to a direct effect of the steroids on cells with degradative potential (MO, osteoclasts) and indicated that such stimulation might be a manifestation of enhanced cell attachment to bone surfaces. Indeed, the data show that GC for 48 h, followed by 24 h of concurrent incubation with TM (0.2 ug/ml) or SW (0.1 g/ml). The cells were then washed and assessed for particle binding as previously described. Note that TM and SW significantly (P < 0.001) inhibit both basal and cortisol-stimulated binding.
Control Dex. Prog. Prog.
Dox.
Dex.
(10-SM) (10-7) (5xe0-) Po P . (10-7) (5xlO-6 Figure 7 . Effect of progesterone on GC-stimulated MO-bone attachment. MO were treated for 48 h with the agents indicated on the abscissa and then subjected to the bone particle binding assay. Note that progesterone alone does not affect binding but significantly inhibits the stimulatory activity of dexamethasone. 
Prog
Prog.
(10a8 M) (5x 10-6M) Dex Figure 8 . Effect of progesterone on GC-stimulated bone resorption.
The resorption assay was performed in the presence of one or both steroids or the ethanol carrier. Note that, as with binding, progesterone alone does not affect resorption but blocks the stimulatory activity of dexamethasone.
promote MO-bone binding and that they do so in a concentration dependent manner which parallels the dose response of GCstimulated, MO-mediated bone resorption (10) . Moreover, the attachment-promoting effect appears to be relatively specific in that GC treatment does not increase the ability of MO to bind to plastic, hydroxyapatite, or collagen. In fact, attachment to plastic is clearly reduced by GC treatment. Cell recognition of, and attachment to, specific substrates are membrane-mediated events and often involve the oligosaccharide moieties of cell surface glycoproteins (for review see reference 15) . This clearly seems to be the case for MO-bone binding (12, 16) and it is, in fact, by altering cell surface oligosaccharides that GC appear to affect the attachment process. This conclusion follows from two series of experiments, the first of which involved the use of inhibitors of glycosylation. We observed that preincubation ofMO with TM (at a concentration that decreases [3H]mannose but not [3H]leucine incorporation [12] ) leads to suppression of basal cell-bone attachment and completely abrogates GC stimulation of such binding. We obtained identical results with SW, an a-mannosidase inhibitor that prevents the processing of high mannose to complex glycoproteins (17) . Having established a role for membrane glycosylation in GC-stimulated MO-bone attachment, we turned next to the specific sugars involved. In a previous study, we had found that GlcNAc and GalNAc residues are essential to MO-bone binding (12) , and we therefore determined whether GC mediate their effect by increasing exposure of these cell-surface saccharides. The present experiments demonstrate that membrane binding of those lectins (DBA, SBA, WGA, and GSA-2) that specifically recognize either GlcNAc or GalNAc is increased after GC treatment. These observations indicate that the steroids enhance exposure ofthese sugars in the MO membrane, and are consistent with findings of altered glycosylation in GC-treated cells (18, 19) . Furthermore, Ramachandran et al. (20) GC are traditionally believed to exert their effects via specific cytosolic receptors which interact with DNA to alter transcriptional activity. On the other hand, some evidence has accumulated which indicates that not all GC effects are receptor mediated (for review see reference 21). Although our study did not directly examine this question, it is interesting that the doses of the GC that enhance bone binding and resorption are in the range of the reported affinity constants of the GC for their receptors (22, 23) . In addition, our data show that progesterone, which competes with GC for the cytosolic receptor (24) , blocks all the GC-stimulated alterations of MO function assessed in this study.
We are aware that our observations seem to contradict those made in organ culture wherein GC usually suppress bone resorption. To resolve this paradox may require both a reconsideration of the life history of osteoclasts and MOs and the realization that GC may affect developing cells in an entirely different manner than mature ones. Osteoclasts are derived from hematopoietic precursor cells that almost certainly belong to the monocyte-macrophage family (25, 26) . However, the precise point at which the lineage of osteoclasts diverges from that of MO (if, indeed, it diverges at all) is not known.
It is clear from this study, the work of Fallon, and other unpublished observations from our laboratory, that GC significantly stimulate the resorptive activity of differentiated, nonproliferative cells of the MO family, i.e., of isolated MO, MO polykaryons (multinucleated giant cells), and bona fide osteoclasts. It is equally clear that GC can profoundly inhibit monocyte and macrophage development. For example, administration of these steroids elicits a monocytopenic response in man (27) and experimental animals (28, 29) ; suppresses in vitro the formation of marrow colony forming units (30, 31) (the committed stem cell of the monocyte-osteoclast family) and of osteoclasts (32) ; blocks the differentiation ofhuman monocytes into macrophages (33) ; and inhibits the fusion of rat macrophages in vitro into multinucleated giant cells (unpublished data).
We suggest, therefore, the following solution to the GC-bone resorption paradox wherein GC have two diametrically opposed effects on bone resorption in vivo and in organ culture, i.e., under circumstances where both precursor and differentiated resorptive cells are present. First, they stimulate matrix degradation by mature MO and osteoclasts. This phenomenon is clearly demonstrated by isolated MO and osteoclasts in vitro (and there is no reason to doubt that there is a similar stimulatory effect in more complex tissue situations). Second, GC inhibit the recruitment and differentiation of cells that belong to the MO-osteoclast family. Thus, both in vivo and in organ culture, the net effect of GC would reflect a summation and thus a balance of both stimulatory and inhibitory activities, with the inhibition of resorption ultimately predominating as osteoclasts are lost through the aging process.
It is interesting to consider this hypothesis in light of the recent observations of Glowacki (34) on the fate of ectopically implanted bone in cortisone-treated rats. Animals given the steroid concurrently with implantation showed almost complete inhibition of the induction of resorbing cells and, consequently, the degradation of the foreign mineralized matrix. On the other hand, if the introduction of cortisone was delayed until after the recruitment of resorptive cells (7-1 1 days), the presence of the steroid significantly stimulated resorptive activity.
